Summary
The psychopharmacological effects of fluvoxamine, 50 mg twice a day, were compared with those of mianserin, 20 mg twice a day, and placebo, each given for 8 days in a double-blind crossover design to 9 healthy human volunteers.
At least one week was left between the 8-day courses of drugs. Testing was carried out before and 3 h after taking the morning dose on Days 1 (predrug), 4, and 8, and comprised EEG, cognitive and psychomotor tasks, and self-ratings of mood and bodily symptoms.
Fluvoxamine had no effect on any of the EEG wavebands, but mianserin increased voltages in the slow wavebands as compared with placebo. This effect was particularly pronounced on Days 4 and 8.
Mianserin significantly decreased critical flicker fusion frequency and speed of reaction time, and slowed down tapping rate; digit symbol substitution and symbol copying test performances were also impaired by mianserin. These effects were most marked after the first dose and had lessened somewhat later in the week. Symbol copying was the only task impaired by fluvoxamine as compared with placebo.
Mianserin caused drowsiness after the first dose but this effect declined by Day 8. By contrast, fluvoxamine induced feelings of anxiety, sweatiness, trembling, nausea, loss of appetite, restlessness, muscle tension, irritability, tiredness, headache, and dizziness; these effects were most evident in the middle of the week and relatively reduced at the end of the week. Mianserin produced a few of these effects but they tended to be maximal on Day 1 or 4 and then to wear off.
It was concluded that fluvoxamine is much less likely to produce psychomotor and cognitive impairment on repeated usage than is mianserin, but that some adverse effects, particularly nausea, may be troublesome. Fluvoxamine would seem more appropriate in patients in whom sedation is not required, mianserin in those in whom initial sedation is acceptable.
Similar content being viewed by others
References
Asberg M, Thoren P, Traskman L, Bertilsson L, Ringberger V (1976) “Serotonin depression” — A biochemical subgroup within the affective disorders? Science 191: 478–480
Claassen V, Davies JE, Hertling G, Placheta P (1977) Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol 60: 505–516
Wilson WH, Higano H, Papadatos Y, Kelwala S, Ban TA (1983) A double-blind placebo-controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers. Br J Clin Pharmacol 15: 385S-392S
Guelfi JD, Dreyfus JF, Pichot P, GEPECEP (1983) A double-blind controlled clinical trial comparing fluvoxamine with imipramine. Br J Clin Pharmacol 15: 411S-417S
Saletu B, Schjerve M, Gruenberger J, Schanda H, Arnold OH (1977) Fluvoxamine: A new serotonin reuptake inhibitor. First clinical and psychometric experience in depressed patients. J Neural Transm 41: 17–36
Wright JH, Denber HCB (1978) Clinical trial of fluvoxamine. A new serotonergic antidepressant. Curr Ther Res 23: 83–89
Lader MH, Curry S, Baker WJ (1980) Physiological and psychological effects of clorazepate in man. Br J Clin Pharmacol 9: 83–90
Bond AJ, Lader MH (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211–218
Saletu B, Grünberger J, Rajna P (1983) Pharmaco-EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine. Br J Clin Pharmacol 15: 369S-384S
Itil TM, Shrivastava RK, Mukherjee S, Coleman BS, Michael ST (1983) A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. Br J Clin Pharmacol 15: 433S-438S
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Curran, H.V., Lader, M. The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects. Eur J Clin Pharmacol 29, 601–607 (1986). https://doi.org/10.1007/BF00635900
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00635900